161 related articles for article (PubMed ID: 27791200)
1. SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug.
Song L; Chang R; Dai C; Wu Y; Guo J; Qi M; Zhou W; Zhan L
Oncotarget; 2017 Feb; 8(6):9108-9122. PubMed ID: 27791200
[TBL] [Abstract][Full Text] [Related]
2. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
[TBL] [Abstract][Full Text] [Related]
3. MiR-142-5p Acts as a Significant Regulator Through Promoting Proliferation, Invasion, and Migration in Breast Cancer Modulated by Targeting SORBS1.
Yu W; Li D; Zhang Y; Li C; Zhang C; Wang L
Technol Cancer Res Treat; 2019; 18():1533033819892264. PubMed ID: 31789129
[TBL] [Abstract][Full Text] [Related]
4. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
5. SORBS1 serves a metastatic role via suppression of AHNAK in colorectal cancer cell lines.
Cho WC; Jang JE; Kim KH; Yoo BC; Ku JL
Int J Oncol; 2020 May; 56(5):1140-1151. PubMed ID: 32319594
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY
Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231
[TBL] [Abstract][Full Text] [Related]
7. PEG-GO@XN nanocomposite suppresses breast cancer metastasis via inhibition of mitochondrial oxidative phosphorylation and blockade of epithelial-to-mesenchymal transition.
Zhang J; Yan L; Wei P; Zhou R; Hua C; Xiao M; Tu Y; Gu Z; Wei T
Eur J Pharmacol; 2021 Mar; 895():173866. PubMed ID: 33454376
[TBL] [Abstract][Full Text] [Related]
8. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
10. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
11. Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition.
Zhu X; Zhong J; Zhao Z; Sheng J; Wang J; Liu J; Cui K; Chang J; Zhao H; Wong S
Oncotarget; 2015 Sep; 6(28):25320-38. PubMed ID: 26318291
[TBL] [Abstract][Full Text] [Related]
12. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
[TBL] [Abstract][Full Text] [Related]
14. SORBS1 inhibits epithelial to mesenchymal transition (EMT) of breast cancer cells by regulating PI3K/AKT signaling and macrophage phenotypic polarization.
Feng K; Di Y; Han M; Yan W; Wang Y
Aging (Albany NY); 2024 Mar; 16(5):4789-4810. PubMed ID: 38451194
[TBL] [Abstract][Full Text] [Related]
15. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
16. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
17. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis.
Wang Z; Liu Y; Lu L; Yang L; Yin S; Wang Y; Qi Z; Meng J; Zang R; Yang G
Oncotarget; 2015 Mar; 6(9):6670-83. PubMed ID: 25749384
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
Liu F; Zhang H; Song H
Oncol Rep; 2017 Jan; 37(1):83-90. PubMed ID: 27878304
[TBL] [Abstract][Full Text] [Related]
20. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
